Allogene Therapeutics
ALLO
173 hedge funds and large institutions have $3.8B invested in Allogene Therapeutics in 2020 Q2 according to their latest regulatory filings, with 68 funds opening new positions, 55 increasing their positions, 37 reducing their positions, and 9 closing their positions.
656% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 9
165% more capital invested
Capital invested by funds: $1.44B → $3.8B (+$2.36B)
74% more call options, than puts
Call options by funds: $15.9M | Put options by funds: $9.13M
50% more funds holding
Funds holding: 115 → 173 (+58)
49% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 37
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
4.89% more ownership
Funds ownership: 59.05% → 63.94% (+4.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$110M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$95.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$64.4M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$57.4M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$37.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$54.2M |
| 2 |
ROTUOC
Regents of the University of California
Oakland,
California
|
-$38.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.8M |
| 4 |
VM
VV Manager
Boston,
Massachusetts
|
-$17.8M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$9.89M |
ALLO Hedge Fund Activity: Q2 2020 in Review
173 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q2 2020, worth a combined $3.8B — up 165% from $1.44B a quarter earlier.
Buyers outnumbered sellers: 68 funds opened new ALLO positions and 9 closed out — a net gain of 59 holders — while 55 added to existing stakes and 37 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $110M. The largest seller was TPG Group Holdings (SBS) Advisors, cutting an estimated $54.2M.
- 173 institutional investors held Allogene Therapeutics (ALLO) as of Q2 2020, up from 115 in Q1 2020.
- Funds reported $3.8B of Allogene Therapeutics stock for Q2 2020, up 165% quarter-over-quarter.
- 68 funds opened new Allogene Therapeutics positions in Q2 2020 and 9 closed out, a net change of +59 holders.
- The largest Allogene Therapeutics buyer in Q2 2020 was Capital Research Global Investors, an estimated $110M added.
- The largest Allogene Therapeutics seller in Q2 2020 was TPG Group Holdings (SBS) Advisors, an estimated $54.2M sold.
Based on aggregated 13F filings for Q2 2020.